The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired





About Archimedes Pharma

Archimedes Pharma is an international specialty pharmaceutical company providing novel and advanced treatments to address unmet needs for people living with serious or life–threatening chronic and debilitating illnesses. Archimedes Pharma has developed proprietary technologies for nasal and oral drug delivery and currently markets a diverse portfolio of specialty products focused on the oncology, pain, and critical care sectors throughout Europe. The company's lead product is PecFent (fentanyl Pectin nasal spray) for the management of breakthrough pain in cancer patients. Breakthrough pain in cancer (BTPc) is characterized by sudden, often unpredictable episodes of intense pain that may last up to 60 minutes and occur despite background pain medication. On average, more than half of patients with cancer experience breakthrough pain.

Archimedes Pharma Headquarter Location

250 South Oak Way Green Park

Reading, England, RG2 6UG,

United Kingdom

+44 (0) 118 931 5050

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Archimedes Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Archimedes Pharma is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Archimedes Pharma News

Tessa Therapeutics Names Biopharma Veteran Jeffrey H. Buchalter to Board of Directors

Mar 1, 2019

Mr. Buchalter brings over three decades of biopharmaceutical industry experience and has an extensive background in commercialization and drug development in oncology. He has held various chairmanships and senior management positions, including serving as Chairman of the Board, President and Chief Executive Officer of Archimedes Pharma. Prior to joining Archimedes, he was Chairman of the Board, President, and Chief Executive Officer of NASDAQ-listed Enzon Pharmaceuticals, and President, Chief Executive Officer, and Director of Ilex Oncology, Inc. He has also served as a senior executive at Pharmacia, Wyeth and Schering-Plough. Underscoring his leadership in the industry, Mr. Buchalter received the American Cancer Society's Joseph F. Buckley Memorial Award for his commitment to cancer control and involvement in the oncology pharmaceutical field. At the invitation of former U.S. President George H. W. Bush, he served as Collaborating Partner in the President's National Dialogue on Cancer. He also served as Chairman of the Board of Directors to the National Childhood Cancer Foundation in the United States. "We are delighted to welcome Jeff to the Tessa board," said Tessa Therapeutics co-founder and CEO, Mr. Andrew Khoo. "His extensive industry leadership experience combined with his deep knowledge of oncology will be a great fit as Tessa moves to our next growth inflection point. Jeff's commercial experience steeped in oncology will be a strong asset to Tessa." Commenting on his new role, Mr. Buchalter said, "I am pleased to be part of Tessa's growth and development at such a critical stage of the company's growth. I am excited to see the clinical progress Tessa has made in the treatment of solid tumors, using their proprietary technology. The strong operational capabilities of the team as well as Tessa's vibrant culture make this a compelling opportunity." Tessa recently announced the addition of Dr. George W. Sledge, Jr., M.D., Professor and Chief of Medical Oncology at the Stanford University Medical Center, to its Board of Directors. About Tessa Therapeutics Tessa Therapeutics is a clinical-stage immunotherapy company focused on the development of autologous and off-the-shelf, allogeneic therapies targeting solid tumors. Tessa's Virus-Specific T cell (VST) platform harnesses the body's potent anti-viral immune response and has shown compelling results in the treatment of solid tumors. Tessa is building a portfolio of innovative, next-generation therapies by combining the qualities of VSTs with other immuno-oncology technologies. This includes a rapidly growing pipeline of clinical and pre-clinical autologous programs that target a wide range of cancers, including nasopharyngeal carcinoma (NPC), cervical cancer, oropharyngeal cancer, liver cancer and lung cancer. In addition, Tessa is leveraging its platform to develop an allogeneic therapy to address Epstein-Barr virus (EBV)-associated lymphomas. Tessa has built up robust operational and supply chain capabilities to successfully deliver T cell therapy treatments to a large patient pool worldwide. Together with the Company's academic, clinical, and commercial research partners, Tessa has created a fully-integrated approach to the treatment of cancer with immunotherapy. For more information on Tessa, please visit . Tessa Therapeutics Media Contacts

  • Where is Archimedes Pharma's headquarters?

    Archimedes Pharma's headquarters is located at 250 South Oak Way, Reading.

  • What is Archimedes Pharma's latest funding round?

    Archimedes Pharma's latest funding round is Acquired.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.